Phase 3 Clinical Trials With Primary Completion Dates in February 2018

This is a list of Phase 3 trials with primary completion dates in February 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ANTHAnthera Pharmaceuticals, Inc.2018-02-01Phase 3NCT03051490RESULT: Reliable, Emergent Solution Using Liprotamase Treatment
BHVNBiohaven Pharmaceutical Holding Company Ltd.2018-02-01Phase 3NCT03237845Safety and Efficacy in Adult Subjects With Acute Migraines
CLSDClearside Biomedical, Inc.2018-02-01Phase 3NCT03097315Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis
CLSDClearside Biomedical, Inc.2018-02-01Phase 3NCT02595398Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
ENDPEndo International plc2018-02-01Phase 3NCT01210352Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
GRFSGrifols, S.A.2018-02-01Phase 3NCT02604810Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
GRFSGrifols, S.A.2018-02-01Phase 3NCT02697292IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
KMPHKemPharm, Inc.2018-02-01Phase 3NCT03292952KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
MESOMesoblast Limited2018-02-01Phase 3NCT02032004Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
MESOMesoblast Limited2018-02-01Phase 3NCT01854567P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
ONTXOnconova Therapeutics, Inc.2018-02-01Phase 3NCT01928537Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
ONTXOnconova Therapeutics, Inc.2018-02-01Phase 3NCT01241500Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
PRAHPRA Health Sciences, Inc.2018-02-01Phase 3NCT02817828E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study